Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
histidine + meloxicam
- Development stage
- Preclinical
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Histidine + meloxicam is a combination therapeutic developed by Physician Therapeutics and marketed under the brand name TREPOXICAM-7.5. It consists of meloxicam, a non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, and L-histidine, an amino acid that serves as a precursor to histamine. The combination is designed to treat pain and inflammation associated with osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis. The inclusion of L-histidine is intended to modulate neurotransmitter pathways involved in pain perception and stimulate the release of adrenocorticotropic hormone (ACTH), potentially enhancing the analgesic effects of meloxicam. This product has not received FDA approval for safety or efficacy.
- Brand names
- TREPOXICAM-7.5TREPOXICAM7.5TREPOXICAM 7.5
- Other names
- L-histidine + meloxicamTrepoxicam
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on histidine + meloxicam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on histidine + meloxicam.